Takeaways: XORTX’s planned Canadian CTA could strengthen XORLO’s regulatory pathway while generating clinical evidence to support a future U.S. NDA. The proprietary oxypurinol formulation ...
Takeaways: The Enoumena–AOP Health partnership could strengthen Sibboran’s position in Canada’s acute-care cardiovascular market by combining local commercialization with established manuf...
Takeaways: Tevimbra’s completed pCPA negotiations strengthen BeOne’s position in Canada’s NPC immunotherapy market and could establish an early publicly funded first-line option. Prov...
Takeaways: Mint’s expanded partnership with Bayer strengthens its position as a Canadian pharmaceutical distribution partner, broadening its footprint across cardiovascular and women’s health. T...
Takeaways: Health Canada’s approval of Dawnzera (donidalorsen) gives CELYSTRA a first‑in‑class, RNA‑targeted prophylaxis for hereditary angioedema (HAE) in patients ≥12 years, with Q4W/Q8W...
Takeaways: Completing pCPA negotiations is a key step toward public reimbursement for Nemluvio in Canada, which—once provincial/territorial drug plans list it—should materially expand access for...
Takeaways: The approval of Nduvra (tapinarof) 1% for moderate to severe atopic dermatitis gives Organon a first‑in‑class, steroid‑free topical that can be prescribed by family physicians w...
Takeaways: Enrolling the first Canadian patient in ReVeRA‑301 advances Milestone’s plan to seek a single‑study sNDA for etripamil in AFib‑RVR, a substantially larger market than its approved PSV...
Takeaways: The Canadian approval expands Epkinly into a second major lymphoma indication (after DLBCL), giving AbbVie a bispecific‑based triplet option in relapsed/refractory follicular ly...
Takeaways: Approval would position Jemperli as a potential first‑line, organ‑preserving immunotherapy for dMMR/MSI‑H locally advanced rectal cancer, opening a new, biomarker‑defined segment with...
